Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY19 results · Jan–Mar 2019
Lincoln Pharmaceuticals reported revenue from operations of ₹77.46 crore and net profit of ₹7.17 crore for Q4 FY19 (Jan–Mar 2019), on a standalone basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 77.46 | — | — | 81.00 | −4.4% |
| Other income | (0.59) | — | — | 0.53 | Turned loss |
| Total income | 76.87 | — | — | 81.54 | −5.7% |
| Profit before tax | 6.96 | — | — | 11.27 | −38.2% |
| Net profit for the period | 7.17 | — | — | 9.45 | −24.1% |
| EPS, basic (₹) | 3.59 | — | — | 4.73 | −24.1% |
| Net margin (%) | 9.3 | — | 11.7 |
Standalone
- Filed with BSE
- 07 Jun 2019, 15:15 IST
- Board meeting
- 30 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE